Key Developments: Syneron Medical Ltd (ELOS.O)
8.69USD
24 May 2013
$-0.11 (-1.25%)
$8.80
$8.75
$8.89
$8.65
104,402
128,249
$11.15
$7.21
Latest Key Developments (Source: Significant Developments)
Syneron Medical Ltd Appoints Hugo Goldman as Chief Financial Officer
Syneron Medical Ltd announced that Hugo Goldman has been appointed Chief Financial Officer, effective immediately. Mr. Goldman replaces David Schlachet, who had been serving as interim Chief Financial Officer since August 2012. Full Article
Syneron Medical Ltd Receives FDA Clearance for me Home-Use Hair Removal System
Syneron Medical Ltd announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the me Home-Use Hair Removal System to consumers (OTC). Full Article
Syneron Medical Ltd Announces Resignation Of Chief Financial Officer
Syneron Medical Ltd announced that Asaf Alperovitz has resigned from the position of Chief Financial Officer to pursue a new career opportunity. Syneron's Board of Directors has appointed David Schlachet as interim Chief Financial Officer, effective as of August 24, 2012, and has initiated an executive search process to find a permanent replacement. Full Article
Syneron Medical Ltd. To Acquire Assets Of TransPharma Medical Ltd
Syneron Medical Ltd. announced that it has signed a definitive agreement to acquire substantially all the assets of TransPharma Medical Ltd. Under terms of the agreement, Syneron will acquire substantially all the assets of TransPharma, including its patent portfolio, for approximately $3.6 million in cash. The acquisition is subject to customary closing conditions. Full Article
Syneron Medical Ltd. Closes Acquisition Of Ultrashape Ltd.
Syneron Medical Ltd. announced that is has closed its previously announced acquisition of Ultrashape Ltd. (Ultrashape), a developer, manufacturer and marketer of non-invasive technologies for fat cell destruction and body sculpting. Terms of the transaction were not disclosed. Full Article
Syneron Medical Ltd. Announces Result Of Clinical Study On Skin Lightening With Elure
Syneron Medical Ltd. announced the publication of results from a clinical study evaluating the skin lightening efficacy and safety of its elure Advanced Skin Lightening product (lignin peroxidase cream) compared with 2% hydroquinone cream. The study, which demonstrated significantly faster and superior skin lightening results with elure, was published in the December 2011 issue of the peer-reviewed Journal of Cosmetic Dermatology. The Journal of Cosmetic Dermatology is the official journal of The International Academy of Cosmetic Dermatology (IACD). The publication, which is titled A Randomized and Placebo-Controlled Study to Compare the Skin Lightening, Efficacy, and Safety of Lignin Peroxidase Cream Versus 2% Hydroquinone Cream. The single-center, randomized, double-blind, placebo-controlled study included 51 patients, all of which were Asian women. Patients were randomized to receive day and night applications of elure Advanced Skin Lightening products on one randomly selected side of their face, and either 2% hydroquinone cream or placebo on the other side of their face. Full Article
Syneron Medical Ltd. To Acquire Ultrashape Ltd.
Syneron Medical Ltd. announced that is has signed a definitive agreement to acquire Ultrashape Ltd. (Ultrashape), a developer, manufacturer and marketer of non-invasive technologies for fat cell destruction and body sculpting. Ultrashape is the sole operating entity of Ultrashape Medical Ltd. and it owns all rights and interests in the fat cell reduction and body sculpting business. Under terms of the agreement, Syneron will acquire 100% of the outstanding shares of Ultrashape Ltd. from Ultrashape Medical Ltd. for $12.0 million in cash. The acquisition is subject to customary closing conditions and is expected to close by the end of the first quarter 2012. Full Article
Syneron Medical Ltd. Announces International Launch Of eLase Laser Hair Removal System
Syneron Medical Ltd. announced the International launch of the eLase with Motif laser hair removal system. The eLase system will be unveiled at CosmoProf Asia 2011, November 9-11, 2011. The eLase system has received CE Mark approval from the European Union and is available in select European and Asian markets. Full Article
Palomar Medical Technologies, Inc. And Syneron Medical Ltd. Announces Settlement Of Patent Infringement Lawsuits
Palomar Medical Technologies, Inc. and Syneron Medical Ltd., the global aesthetic device company, announced that they have entered into a comprehensive settlement agreement ending the patent disputes between the companies on mutually agreeable terms. The comprehensive settlement agreement includes two Non-Exclusive Patent License Agreements by Palomar with Candela Corporation (acquired by Syneron in January 2010) and Syneron. Under the first Agreement, Palomar grants to Candela and Syneron a non-exclusive, worldwide, fully paid-up, irrevocable license to U.S. Patent Nos. 5,735,844 and 5,595,568 and foreign counterparts for their professional laser- and lamp-based hair removal systems. Under this Agreement, Candela and Syneron will pay Palomar $31 million by September 19, 2011. In addition, Palomar will receive a royalty-free license to certain Candela patents. Under the second Agreement, Palomar will grant to Syneron and affiliates a non-exclusive, royalty bearing, license in the United States to U.S. Patent Nos. 5,735,844 and 5,595,568 for consumer home-use lamp-based hair removal products. Syneron will pay Palomar on sales in the United States a 5.0% royalty up to an undisclosed amount of cumulative sales, then 6.5% up to the next undisclosed amount of cumulative sales, and 7.5% on all cumulative sales thereafter. In addition, Palomar will receive a royalty-free license to certain Syneron and Candela patents. Full Article
Syneron Medical Ltd.'s Syneron Beauty Receives FDA Clearance For New Tanda Luxe Device For Treatment Of Periorbital Wrinkles At Home
Syneron Medical Ltd. announced that Syneron Beauty, a subsidiary of Syneron Medical Ltd., announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the new Taenda Luxe Light Emitting Diode device to consumers (OTC). The new device is a evolution of the Taenda Regenerate, and is cleared by the FDA for over-the-counter treatment of wrinkles, rhytides and fine lines around the periorbital (around the eye) region. Syneron Beauty expects to begin commercialization of the Taenda Luxe wrinkle treatment device in the fourth quarter in the prestige retail consumer market. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
